Assay for glycated blood proteins

• US 5,919,708 A
• Filed: 12/11/1995
• Issued: 07/06/1999
• Est. Priority Date: 11/14/1990
• Status: Expired due to Fees

• Current Assignee: Axis-Shield ASA (Abbott Laboratories)
• Original Assignee: Axis Biochemicals AS
• Inventors: Sundrehagen, Erling
• Primary Examiner(s): Snay, Jeffrey
• Application Number:
  US08/570,569
• Time in Patent Office: 1,303 Days
• Field of Search: 436/66, 436/67, 436/87, 436/88, 436/161, 436/166, 436/175, 436/177, 436/815, 436/824, 436/172, 436/178, 436/536, 436/539
• US Class Current: 436/66
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92
• CPC Class Codes: G01N 33/6842 Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
• CPC Class Codes: G01N 33/723 Glycosylated haemoglobin
• CPC Class Codes: Y10S 436/815 Test for named compound or class of compounds
• CPC Class Codes: Y10S 436/824 Immunological separation techniques
• CPC Class Codes: Y10T 436/25125 Digestion or removing interfering materials
• CPC Class Codes: Y10T 436/25375 Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Abstract

A method of assessing glycated blood protein in a sample which comprises separating glycated and non-glycated protein using a liquid phase precipitation reagent, contacting the sample with a signal forming agent capable of binding preferentially to the glycated protein, and assessing the signal forming agents.

Claims

1. A method of assessing a glycated blood protein in a sample, said method comprising the steps of:

a) optionally hemolyzing said sample to liberate cell bound glycated blood protein;

b) separating said glycated blood protein and the corresponding non-glycated blood protein from said sample using a liquid phase precipitation agent, or means substantially specific for the protein being assessed;

c) contacting said non-immobilized separated proteins with a first signal forming agent capable of binding to said glycated protein with substantially higher binding affinity than for the corresponding non-glycated protein;

d) optionally, contacting said non-immobilized separated proteins with a second signal forming agent capable of binding to said glycated protein and to said corresponding non-glycated protein; and

e) assessing the signal forming agents which have bound to said non-immobilized separated proteins or which have not bound to said glycated protein or said corresponding non-glycated protein;

with the proviso that where said glycated protein comprises glycated hemoglobin said first signal forming agent is a chromophore labelled boronic acid or salt thereof having an absorption maximum at above 600 nm.

2. A method as claimed in claim 1, wherein step (c) is effected using two different first signal forming agents, each substantially specific for a different glycated blood protein, and optionally step (d) is effected using two different second signal forming agents substantially specific for the same two different blood proteins.

3. A method as claimed in claim 1 wherein said first signal forming agent comprises a conjugate of one or more dihydroxyboryl residues, or salts thereof, linked to a signal forming label.

4. A method as claimed in claim 1 wherein precipitation is achieved by addition of metallic cations.

5. A method as claimed in claim 1 wherein precipitation is achieved by addition of an organic solvent or mixture of organic solvents, in a concentration which is able substantially specifically to precipitate the protein being assessed.

6. A method as claimed in claim 1 wherein precipitation is achieved by addition of binding proteins specific for the protein being assessed.

7. A method as claimed in claim 1 wherein the precipitation step takes place on or within a solid phase.

8. A method as claimed in claim 1 wherein the precipitate so formed is separated by means of a chromatography or filtration medium or by centrifugation.

9. A method as claimed in claim 1 wherein the second signal forming agent binds substantially specifically to said glycated and corresponding non-glycated protein.

10. A method as claimed in claim 1 wherein the second signal forming agent binds, non-specifically to blood proteins.

11. A method as claimed in claim 1 for the assessment of glycated albumin or glycated complement C3.

12. A method as claimed in claim 1 for the assessment of glycated albumin and glycated complement C3.

13. A method as claimed in claim 11 for the assessment of glycated albumin, wherein the second signal forming agent is selected from the group consisting of metal salts, metal chelates, anionic dyes, porphyrins and synthetic derivatives thereof, ponceau S, coomassie brilliant blue, bicinchoninic acid, and bromophenol blue.

14. A method as claimed in claim 12 for the assessment of glycated albumin, wherein the second signal forming agent is selected from the group consisting of metal salts, metal chelates, anionic dyes, porphyrins and synthetic derivatives thereof, ponceau S, coomassie brilliant blue, bicinchoninic acid, and bromophenol blue.

15. A method of assessing a glycated blood protein in a sample, said method comprising the steps of:

a) optionally hemolyzing said sample to liberate cell bound glycated blood protein;

b) separating said glycated blood protein and the corresponding non-glycated blood protein from said sample using a liquid phase precipitation agent, or means substantially specific for the protein being assessed;

c) subsequently contacting said non-immobilized separated proteins with a first signal forming agent capable of binding to said glycated protein with substantially higher binding affinity than for the corresponding non-glycated protein;

d) optionally, contacting said non-immobilized separated proteins with a second signal forming agent capable of binding to said glycated protein and to said corresponding non-glycated protein; and

e) assessing the signal forming agents which have bound to said non-immobilized separated proteins and which have not bound to said glycated protein or said corresponding non-glycated protein;

with the proviso that where said glycated protein comprises glycated hemoglobin said first signal forming agent is a chromophore labelled boronic acid or salt thereof having an absorption maximum at above 600 nm.

16. A method as claimed in claim 15, wherein step (c) is effected using two different first signal forming agents, each substantially specific for a different glycated blood protein, and optionally step (d) is effected using two different second signal forming agents substantially specific for the same two different blood proteins.

17. A method as claimed in claim 15 wherein said first signal forming agent comprises a conjugate of one or more dihydroxyboryl residues, or salts thereof, linked to a signal forming label.

20. A method as claimed in claim 16 wherein precipitation is achieved by addition of binding proteins specific for the protein being assessed.

21. A method as claimed in claim 15 wherein the precipitation step takes place on or within a solid phase.

22. A method as claimed in claim 15 wherein the precipitate so formed is separated by means of a chromatography or filtration medium or by centrifugation.

23. A method as claimed in claim 15 wherein the second signal forming agent binds substantially specifically to said glycated and corresponding non-glycated protein.

24. A method as claimed in claim 15 wherein the second signal forming agent binds non-specifically to blood proteins.

25. A method as claimed in claim 15 for the assessment of glycated albumin or glycated complement C3.

26. A method as claimed in claim 15 for the assessment of glycated albumin and glycated complement C3.

27. A method as claimed in claim 25 for the assessment of glycated albumin, wherein the second signal forming agent is selected from the group consisting of metal salts, metal chelates, anionic dyes, porphyrins and synthetic derivatives thereof, ponceau S, coomassie brilliant blue, bicinchoninic acid, and bromophenol blue.

28. A method as claimed in claim 26 for the assessment of glycated albumin, wherein the second signal forming agent is selected from the group consisting of metal salts, metal chelates, anionic dyes, porphyrins and synthetic derivatives thereof, ponceau S, coomassie brilliant blue, bicinchoninic acid, and bromophenol blue.

18. A method as claimed in claim 18 wherein precipitation is achieved by addition of metallic cations.

19. A method as claimed in claim 18 wherein precipitation is achieved by addition of an organic solvent or mixture of organic solvents, in a concentration which is able substantially specifically to precipitate the protein being assessed.